Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1274-1281

  Gupta, Vikas ^a   Gotlib, Jason ^b   Radich, Jerald P ^c   Kröger, Nicolaus M ^d   Rondelli, Damiano ^e   Verstovsek, Srdan ^f   Deeg, H Joachim ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF ILLINOIS   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Homologous; INCB018424; Janus kinase 1; Primary myelofibrosis; Transplantation

Indexed keywords

JANUS KINASE;

ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; PRIMARY MYELOFIBROSIS; PROCEDURES;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84905574606     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.03.017     Document Type: Review

References (73)

1. Mehta J., Wang H., Iqbal S.U., Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2014, 55:595-600.
2. McLornan D.P., Mead A.J., Jackson G., Harrison C.N. Allogenic stem cell transplantation for MF in 2012. Brit J Haematol 2012, 157:413-425.
3. Barosi G., Mesa R.A., Thiele J., et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for MF Research and Treatment. Leukemia 2008, 22:437-438.
4. Deeg H.J., Gooley T.A., Flowers M.E., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912-3918.
5. Gupta V., Hari P., Hoffman R. Allogeneic hematopoietic cell transplantation for MF in the era of JAK inhibitors. Blood 2012, 120:1367-1379.
6. Thiele J., Kvasnicka H.M., Dietrich H., et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005, 20:879-889.
7. Samuelson S., Sandmaier B.M., Heslop H.E., et al. Allogeneic haematopoietic cell transplantation for MF in 30 patients 60-78 years of age. Br J Haematol 2011, 153:76-82.
8. Alchaby H., Badbaran A., Zabelina T., et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010, 116:3572-3581.
9. Gupta V., Malone A.K., Hari P.N., et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2014, 20:89-97.
10. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105:4115-4119.
11. Kroger N., Holler E., Kobbe G., et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:5264-5270.
12. Jaekel N., Behre G., Behning A., et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant 2014, 49:179-184.
13. Kröger N., Alchalby H., Ditschkowski M., et al. Ruxolitinib as pretreatment before allogeneic stem cell transplantation for myelofibrosis. Blood 2013, 122. ASH Meeting Abstract, abstract 392.
14. Robin M., Francois S., Huynh A., et al. Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO Study, a phase II trial sponsored by Goelams-FIM in collaboration with the sfgmtc. Blood 2013, 122. ASH Meeting Abstract, abstract 306.
15. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
16. Cervantes F., Dupriez B., Pereira A., et al. New prognostic scoring system for primary MF based on a study of the International Working Group for MF Research and Treatment. Blood 2009, 113:2895-2901.
17. Passamonti F., Cervantes F., Vannucchi A.M., et al. Adynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
18. Gangat N., Caramazza D., Vaidya R., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. JClin Oncol 2011, 29:392-397.
19. Vannucchi A.M., Lasho T.L., Guglielmelli P., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, 27:1861-1869.
20. Guglielmelli P., Lasho T.L., Biamonte F., et al. Effect of the number of prognostically relevant mutated genes on survival and leukemia progression in primary myelofibrosis. Blood 2013, 122. ASH Meeting Abstract, abstract 104.
21. Klampfl T., Gisslinger H., Harutyunyan A.S., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. NEngl J Med 2013, 369:2379-2390.
22. Nangalia J., Massie C.E., Baxter E.J., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. NEngl J Med 2013, 369:2391-2405.
23. Sorror M.L., Maris M.B., Storb B., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
24. Rondelli D., Goldberg J.D., Marchioli R., et al. Results of phase II clinical trial MPD-RC 101: allogeneic hematopoietic stem cell transplantation conditioned with fludarabine/melphalan in patients with myelofibrosis. Biol Blood Marrow Transplant 2012, 18:S216.
25. Bacigalupo A., Soraru M., Dominietto A., et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010, 45:458-463.
26. Scott B.L., Gooley T.A., Sorror M.L., et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012, 119:2657-2664.
27. Ditschkowski M., Elmaagacli A.H., Trenschel R., et al. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica 2012, 97:1574-1581.
28. Alchalby H., Yunus D.R., Zabelina T., et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012, 157:75-85.
29. Akpek G., Pasquini M.C., Logan B., et al. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant 2013, 48:825-831.
30. Ballen K. How to manage the transplant question in myelofibrosis. Blood Cancer J 2012, 2:e59.
31. Robin M., Giannotti F., Deconinck E., et al. Outcomes after unrelated cord blood transplantation for adults with primary or secondary myelofibrosis: a retrospective study on behalf of Eurocord and Chronic Malignancy Working Party-EBMT. Blood 2013, 122. ASH Meeting Abstract, abstract 306.
32. Kerbauy D.M., Gooley T.A., Sale G.E., et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007, 13:355-365.
33. Ballen K.K., Shrestha S., Sobocinski K.A., et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010, 16:358-367.
34. Patriarca F., Bacigalupo A., Sperotto A., et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008, 93:1514-1522. on behalf of the GITMO.
35. Robin M., Tabrizi R., Mohty M., et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 2011, 152:331-339.
36. Wong K.M., Atenafu E.G., Kim D., et al. Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1589-1599.
37. Ruutu T., Eriksson B., Remes K., et al. Nordic Bone Marrow Transplantation Group. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002, 100:1977-1983.
38. Rezvani A.R., McCune J.S., Storer B.E., et al. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant 2013, 19:1033-1039.
39. Clift R.A., Buckner C.D., Appelbaum F.R., et al. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 1998, 92:1455-1456.
40. Antin J.H., Ferrara J.L. Cytokine dysregulation and acute graft versus-host disease. Blood 1992, 80:2964-2968.
41. Guardiola P., Anderson J.E., Bandini G., et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999, 93:2831-2838.
42. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
43. Baron F., Sandmaier B.M. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006, 20:1690-1700.
44. Patriarca F., Bacigalupo A., Sperotto A., et al. Outcome of allogeneic stem cell transplantation following reduced-intensity conditioning in patients with idiopathic myelofibrosis: the G.I.T.M.O. experience. Mediterr J Hematol Infect Dis 2010, 2:e2010010.
45. ClinicalTrials.gov. Reduced intensity conditioning versus myeloablative conditioning for acute myeloid leukemia or myelodysplastic syndrome (BMT CTN 0901). Available at: Accessed July 29,2013. http://clinicaltrials.gov/ct2/show/NCT01339910.
46. Verstovsek S., Kantarjian H.M., Estrov Z., et al. Long-term outcomes of107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012, 120:1202-1209.
47. Jakafi prescribing information. Incyte Corporation, Wilmington, DE; June 2013. Available at: Accessed July2013. http://www.incyte.com/sites/default/files/Jakafi_PI.pdf.
48. Verstovsek S., Kantarjian H., Mesa R., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. NEng J Med 2010, 363:1117-1127.
49. Harrison C., Kiladjian J.J., Al-Ali H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. NEng J Med 2012, 366:787-798.
50. Verstovsek S., Mesa R.A., Gotlib J.R., et al. Adouble-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. NEng J Med 2012, 366:799-807.
51. Verstovsek S., Mesa R.A., Gotlib J., et al. Efficacy, safety and survival withruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013, 98:1865-1871.
52. Pardanani A., Gotlib J.R., Jamieson C., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. JClin Oncol 2011, 29:789-796.
53. Pardanani A, Tefferi A, Jamieson C, etal. Long-term follow up of a randomized phase II study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF). ASH Meeting Abstracts Blood 2013;122. abstract4047.
54. Komrokji R., Wadleigh M., Seymour J., et al. Results of a phase 2 study of pacritinib (SB1518) a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombycythemia myelofibrosis. Blood 2011, 118. ASH Annual Meeting Abstracts, abstract 282.
55. Clinicaltrials.gov. Oral pacritinib versus best available therapy totreat myelofibrosis. Available at: Accessed August 13,2013. http://clinicaltrials.gov/show/NCT01773187.
56. Pardanani A., Gotlib J., Gupta V., et al. An expanded multicenter study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis. Blood 2011, 118. ASH Annual Meeting Abstracts, abstract 3849.
57. Pardanani A., Gotlib J., Gupta V., et al. Phase I/II study of CYT387, a JAK1/JAK2 inhibitor for the treatment of myelofibrosis. Blood 2012, 120. ASH Annual Meeting Abstracts, abstract 3849.
58. Sonbol M.B., Firwana B., Zarzour A., et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 2013, 4:15-35.
59. Koppikar P., Bhagwat N., Kilipivaara O., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489:155-159.
60. Saussele S., Lauseker M., Grathwohl A., et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010, 115:1880-1885. for the German Study Group.
61. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. NEng J Med 2006, 355:2408-2417. for the IRIS Investigators.
62. Bacher U., KlyuchnIkov E., Zabelina T., et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia-a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 2009, 88:1237-1247.
63. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEngl J Med 2010, 362:2251-2259.
64. Kantarjian H.M., Hochhaus A., Saglio G., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011, 12:841-851.
65. Radich J.P., Kopecky K.J., et al. Arandomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012, 120:3898-3905.
66. National Comprehensive Cancer Network. Chronic myelologenous leukemia. Available at: Accessed on August 12,2013. http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf.
67. Baccarani M., Deininger M.W., Rosti G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
68. Oehler V.G., Gooley T., Snyder D.S., et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007, 109:1782-1789.
69. Verstovsek S., Mesa R., Gotlib J., et al. Long-Term outcomes of ruxolitinib therapy In patients with myelofibrosis: 3-Year update from COMFORT-I. Blood 2013, 122. ASH Meeting Abstracts, abstract 396.
70. Mesa R.A., Nagomey D.S., Schwager S., et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Blood 2006, 107:361-370.
71. Kvasnicka H.M., Thiele J., Bueso-Ramos C.E., et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. ASCO 2013, Abstract 7030.
72. Kvasnicka HM, Thiele J, Bueso-Ramos CE, etal. Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy. 2013 Congress of the European Hematology Association. Abstract S591.
73. Stübig T., Alchalby H., Ditschkowski M., et al. JAK Inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post ET/PV myelofibrosis. Leukemia 2014, 10.1038/leu.2014.86.